RA Capital Healthcare Fund LP
CIK 1315082 · last filed 2026-06-05
RA Capital Healthcare Fund LP is a corporate insider who has filed 84 SEC Form 4 insider transactions across 41 companies since 2008. The most recent filing, for ABOS, was dated Jun 5, 2026. Across all open-market trades the lifetime net is +$2.42B, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.11B across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.11B
Companies
41
Total Filings
84
Lifetime Open-Market Net
$2.42B
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ABOS | Director | 48,300 | $2.37 | $114.5K | $0 | 1 | 2026-06-05 |
| COAG | 10%+ Owner | 6,325,914 | — | — | $5.07M | 1 | 2026-05-11 |
| VOR | Director | 2,402,095 | $14.36 | $34.49M | -$126.49M | 5 | 2026-04-24 |
| ACRV | Director | 426,302 | $1.48 | $630.9K | $0 | 2 | 2026-04-23 |
| BCAX | Director | 4,603,418 | $21.69 | $99.85M | $24.00M | 2 | 2026-03-02 |
| WVE | Director | 18,203,009 | $5.87 | $106.85M | $26.8K | 2 | 2025-11-14 |
| PEPG | Director | 207,672 | $1.47 | $305.3K | $286.06M | 3 | 2025-09-30 |
| TYRA | Director | 9,695,820 | $26.99 | $261.69M | $157.94M | 3 | 2025-06-06 |
| MLYS | Director | 1,867,229 | $23.62 | $44.10M | $87.50M | 1 | 2025-03-17 |
| Cidara Therapeutics, Inc. (CDTX) Delisted | Director | 1,092,796 | $221.38 | $241.92M | $0 | 3 | 2025-01-07 |
| FDMT | 10%+ Owner | 4,563,211 | $8.83 | $40.29M | $0 | 1 | 2024-12-10 |
| JANX | Director | 1,048,406 | $13.56 | $14.22M | $299.34M | 2 | 2024-10-22 |
| FULC | 10%+ Owner | 3,109,704 | $3.45 | $10.73M | $100.00M | 2 | 2024-08-23 |
| NKTX | Director | 754,311 | $2.86 | $2.16M | $150.00M | 2 | 2024-06-14 |
| SPRY | Director | 9,452,119 | $9.76 | $92.25M | $66.45M | 1 | 2024-03-27 |
| 89bio, Inc. (ETNB) Delisted | Director | 12,431,584 | $14.84 | $184.48M | $509.50M | 6 | 2024-03-06 |
| BDTX | Director | 3,213,828 | $1.75 | $5.62M | $23.40M | 1 | 2023-07-07 |
| IMRA | 10%+ Owner | 2,122,465 | $17.02 | $36.12M | $7.44M | 2 | 2023-02-27 |
| HOWL | Director | 5,701,056 | $0.38 | $2.17M | $32.90M | 2 | 2023-01-10 |
| ANTX | 10%+ Owner | 3,773,517 | $4.74 | $17.89M | $71.7K | 1 | 2022-08-05 |
| Jade Biosciences, Inc. (AVTE) Delisted | Director | — | $93.80 | — | $0 | 1 | 2022-06-22 |
| Icosavax, Inc. (ICVX) Delisted | Director | 5,324,897 | $15.31 | $81.52M | $0 | 1 | 2022-06-14 |
| SLDB | Director | — | $7.14 | — | $0 | 1 | 2022-06-09 |
| CTKB | Director | 13,139,327 | $3.96 | $52.03M | $365.07M | 4 | 2022-03-16 |
| POINT Biopharma Global Inc. (RACA) Delisted | Director | 1,098,318 | $10.27 | $11.28M | $6.27M | 1 | 2021-06-30 |
| Forma Therapeutics Holdings, Inc. (FMTX) Delisted | 10%+ Owner | 1,511,425 | $20.01 | $30.24M | $240.00M | 2 | 2021-04-05 |
| scPharmaceuticals Inc. (SCPH) Delisted | 10%+ Owner | 2,838,034 | $5.67 | $16.09M | $6.78M | 3 | 2021-03-16 |
| Orchard Therapeutics plc (ORTX) Delisted | Director | 9,397,312 | $16.70 | $156.94M | $14.25M | 2 | 2021-02-11 |
| PCVX | 10%+ Owner | 5,169,254 | $47.46 | $245.33M | -$54.09M | 1 | 2020-10-09 |
| KALA | Director | 10,874,613 | $2.63 | $28.60M | $150.00M | 1 | 2020-03-13 |
| Synthorx, Inc. (THOR) Delisted | 10%+ Owner | 0 | — | — | $0 | 1 | 2020-01-24 |
| Eidos Therapeutics, Inc. (EIDX) Delisted | 10%+ Owner | 1,103,847 | — | — | $54.00M | 1 | 2018-06-22 |
| Dicerna Pharmaceuticals Inc (DRNA) Delisted | 10%+ Owner | 5,074,013 | $38.22 | $193.93M | $0 | 2 | 2017-12-20 |
| G1 Therapeutics, Inc. (GTHX) Delisted | 1,723,304 | $7.15 | $12.32M | $18.00M | 1 | 2017-05-24 | |
| ACRS | 10%+ Owner | 2,586,190 | $4.32 | $11.17M | $465.2K | 1 | 2016-01-20 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | 3,751,593 | $0.18 | $666.3K | $8.17M | 4 | 2015-02-18 | |
| ACHILLION PHARMACEUTICALS INC (ACHN) Delisted | 10%+ Owner | 11,739,346 | — | — | -$20.40M | 6 | 2015-01-20 |
| DERMA SCIENCES, INC. (DSCI) Delisted | 10%+ Owner | 1,994,876 | — | — | $134.9K | 1 | 2013-05-01 |
| BIOSPECIFICS TECHNOLOGIES CORP (BSTC) Delisted | 10%+ Owner | 814,940 | — | — | $804.3K | 2 | 2009-04-07 |
| ARADIGM CORP (ARDM) Delisted | 10%+ Owner | 6,681,410 | — | — | -$1.75M | 1 | 2008-10-08 |
| SEQUENOM INC (SQNM) Delisted | 10%+ Owner | 4,646,466 | — | — | $13.79M | 3 | 2008-06-13 |
Recent Filings
84 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-05 | ABOS | Grant (A) | +177,500 | $0 | EDGAR |
| 2026-05-11 | COAG | Buy (P) | +205,032 | $5.07M | EDGAR |
| 2026-04-24 | VOR | Sell (S) | −660,600 | -$10.42M | EDGAR |
| 2026-04-23 | ACRV | Grant (A) | +19,444,440 | $35.00M | EDGAR |
| 2026-04-15 | VOR | Sell (S) | −2,951,956 | -$47.53M | EDGAR |
| 2026-03-02 | BCAX | Buy (P) | +1,500,000 | $24.00M | EDGAR |
| 2025-12-19 | VOR | Grant (A) | −18,501,384 | -$200.00M | EDGAR |
| 2025-11-14 | WVE | Buy (P) | +4,000 | $26.8K | EDGAR |
| 2025-11-03 | — | Disp (D) | −99,448,415 | $0 | |
| 2025-10-17 | VOR | Sell (S) | −2,320,125 | -$68.54M | EDGAR |
Showing 1–10 of 84
Page 1 of 9
Next
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.